Chih‐Hung Hsu
National Taiwan University(TW)Chang Gung Memorial Hospital(TW)Linkou Chang Gung Memorial Hospital(TW)National Taiwan University Hospital(TW)Taipei Medical University(TW)Fujian University of Technology(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Hepatocellular Carcinoma Treatment and Prognosis, Esophageal Cancer Research and Treatment, Gastric Cancer Management and Outcomes, Lung Cancer Treatments and Mutations
Most-Cited Works
- Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.(2001)
- → Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial(2019)1,204 cited
- → Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer(2020)1,151 cited
- → Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study(2013)766 cited
- → Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma(2022)590 cited
- → Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study(2020)559 cited